{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:34:29Z","timestamp":1786988069725,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7212149"],"award-info":[{"award-number":["7212149"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013087","name":"Qingdao Collaborative Innovation Center of Marine Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013087","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973170"],"award-info":[{"award-number":["81973170"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273777"],"award-info":[{"award-number":["82273777"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejmech.2023.115763","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T11:46:58Z","timestamp":1692964018000},"page":"115763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Novel ProTide prodrugs of 5-fluoro-2\u2032-deoxyuridine for the treatment of liver cancer"],"prefix":"10.1016","volume":"260","author":[{"given":"Leilei","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenmin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjun","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6428-9729","authenticated-orcid":false,"given":"Dongdong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengbiao","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxiang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115763_bib1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41586-019-0987-8","article-title":"Human Proteome Project, Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma","volume":"567","author":"Jiang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115763_bib2","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Ca - Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2023.115763_bib3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","article-title":"Targeted therapy for hepatocellular carcinoma","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2023.115763_bib4","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.3390\/cancers14112798","article-title":"Emerging therapies for hepatocellular carcinoma (HCC)","volume":"14","author":"Chakraborty","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2023.115763_bib5","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.gendis.2020.01.014","article-title":"Advances in the early diagnosis of hepatocellular carcinoma","volume":"7","author":"Wang","year":"2020","journal-title":"Genes Dis"},{"key":"10.1016\/j.ejmech.2023.115763_bib6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12935-018-0538-7","article-title":"Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight","volume":"18","author":"Lohitesh","year":"2018","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejmech.2023.115763_bib7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrc.2016.50","article-title":"Chemotherapy: clocking up resistance","volume":"16","author":"Zuccala","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2023.115763_bib8","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3390\/cancers14061462","article-title":"Chemotherapy resistance: role of mitochondrial and autophagic components","volume":"14","author":"Bahar","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2023.115763_bib9","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1101\/gad.333864.119","article-title":"Targeted chemotherapy overcomes drug resistance in melanoma","volume":"34","author":"Yue","year":"2020","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2023.115763_bib10","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1039\/C8DT00838H","article-title":"The side effects of platinum-based chemotherapy drugs: a review for chemists","volume":"47","author":"Oun","year":"2018","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2023.115763_bib11","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.3390\/cancers14092324","article-title":"Sinonasal side effects of chemotherapy and\/or radiation therapy for head and neck cancer: a literature review","volume":"14","author":"Riva","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2023.115763_bib12","doi-asserted-by":"crossref","first-page":"i4567","DOI":"10.1136\/bmj.i4567","article-title":"Anticancer chemotherapy in teenagers and young adults: managing long term side effects","volume":"354","author":"Ahmad","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ejmech.2023.115763_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107447","article-title":"5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future","volume":"206","author":"Vodenkova","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2023.115763_bib14","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s13402-020-00529-1","article-title":"Pharmacogenomics of 5-fluorouracil in colorectal cancer: review and update","volume":"43","author":"Xie","year":"2020","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.ejmech.2023.115763_bib15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/bjc.1994.259","article-title":"Continuous 5-fluorouracil in the treatment of breast cancer","volume":"70","author":"Cameron","year":"1994","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2023.115763_bib16","doi-asserted-by":"crossref","DOI":"10.1159\/000527196","article-title":"Recurrence pattern comparing preoperative chemoradiotherapy and preoperative chemotherapy with docetaxel plus 5-fluorouracil and cisplatin for advanced esophageal cancer","author":"Sugase","year":"2022","journal-title":"Oncology"},{"key":"10.1016\/j.ejmech.2023.115763_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.971475","article-title":"Inhibitory of active dual cancer targeting 5-Fluorouracil nanoparticles on liver cancer in vitro and in vivo","volume":"12","author":"Cheng","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2023.115763_bib18","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/annonc\/mdm599","article-title":"Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy","volume":"19","author":"Soong","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2023.115763_bib19","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3892\/or.2014.3299","article-title":"Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer","volume":"32","author":"Ochiai","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2023.115763_bib20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003088-198916040-00002","article-title":"Clinical pharmacology of 5-fluorouracil","volume":"16","author":"Diasio","year":"1989","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2023.115763_bib21","doi-asserted-by":"crossref","first-page":"14379","DOI":"10.1021\/acs.chemrev.6b00209","article-title":"Metabolism, biochemical actions, and chemical synthesis of anticancer nucleosides, nucleotides, and base analogs","volume":"116","author":"Shelton","year":"2016","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2023.115763_bib22","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2023.115763_bib23","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/jcp.1041040305","article-title":"Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells","volume":"104","author":"Wohlhueter","year":"1980","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ejmech.2023.115763_bib24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2174\/1389557043403936","article-title":"Aryloxy phosphoramidate triesters as pro-tides","volume":"4","author":"Cahard","year":"2004","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115763_bib25","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1021\/acs.jmedchem.7b00734","article-title":"The ProTide prodrug technology: from the concept to the clinic","volume":"61","author":"Mehellou","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115763_bib26","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/17460441.2021.1922385","article-title":"An overview of ProTide technology and its implications to drug discovery","volume":"16","author":"Serpi","year":"2021","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115763_bib27","first-page":"1567","volume":"76","author":"Greig","year":"2016","journal-title":"Sofosbuvir\/Velpatasvir: A Review in Chronic Hepatitis C, Drugs"},{"key":"10.1016\/j.ejmech.2023.115763_bib28","first-page":"1017","volume":"77","author":"Scott","year":"2017","journal-title":"Tenofovir Alafenamide: A Review in Chronic Hepatitis B, Drugs"},{"key":"10.1016\/j.ejmech.2023.115763_bib29","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1001\/jama.2020.16337","article-title":"Efficacy of remdesivir in COVID-19","volume":"324","author":"McCreary","year":"2020","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.ejmech.2023.115763_bib30","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1158\/1078-0432.CCR-20-4403","article-title":"A phase ib open-label, dose-escalation study of NUC-1031 in combination with carboplatin for recurrent ovarian cancer","volume":"27","author":"Kazmi","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115763_bib31","doi-asserted-by":"crossref","first-page":"8179","DOI":"10.1021\/acs.jmedchem.0c02194","article-title":"Single diastereomers of the clinical anticancer ProTide agents NUC-1031 and NUC-3373 preferentially target cancer stem cells in vitro","volume":"64","author":"Slusarczyk","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115763_bib32","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1021\/jm401853a","article-title":"Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development","volume":"57","author":"Slusarczyk","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115763_bib33","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1158\/1078-0432.CCR-21-1652","article-title":"The novel nucleoside analogue ProTide NUC-7738 overcomes cancer resistance mechanisms in vitro and in a first-in-human phase I clinical trial","volume":"27","author":"Schwenzer","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115763_bib34","doi-asserted-by":"crossref","first-page":"7247","DOI":"10.1021\/jm200815w","article-title":"Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside","volume":"54","author":"McGuigan","year":"2011","journal-title":"J. Med. Chem."},{"issue":"15_suppl","key":"10.1016\/j.ejmech.2023.115763_bib35","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS3617","article-title":"NuTide 302: a phase IB study to assess the safety, pharmacokinetics and clinical activity of NUC-3373 in combination with standard agents used in colorectal cancer treatment","volume":"36","author":"Blagden","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115763_bib36","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1021\/jm800594c","article-title":"Phosphate prodrugs derived from N-acetylglucosamine have enhanced chondroprotective activity in explant cultures and represent a new lead in antiosteoarthritis drug discovery","volume":"51","author":"McGuigan","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115763_bib37","doi-asserted-by":"crossref","first-page":"16425","DOI":"10.1021\/acs.jmedchem.1c01444","article-title":"Discovery of modified amidate (ProTide) prodrugs of tenofovir with enhanced antiviral properties","volume":"64","author":"Kalcic","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115763_bib38","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1021\/acs.jmedchem.5b01807","article-title":"Discovery of an orally active and liver-targeted prodrug of 5-fluoro-2'-deoxyuridine for the treatment of hepatocellular carcinoma","volume":"59","author":"Peng","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115763_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128405","article-title":"Synthesis and antiviral effect of phosphamide modified vidarabine for treating HSV 1 infections","volume":"52","author":"Wang","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115763_bib40","doi-asserted-by":"crossref","first-page":"20154","DOI":"10.1002\/anie.202008665","article-title":"The enzyme-free release of nucleotides from phosphoramidates depends strongly on the amino acid","volume":"59","author":"Jovanovic","year":"2020","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2023.115763_bib41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1021\/acsmedchemlett.0c00485","article-title":"Influence of 4'-substitution on the activity of gemcitabine and its ProTide against VZV and SARS-CoV-2","volume":"12","author":"Zheng","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115763_bib42","doi-asserted-by":"crossref","first-page":"12044","DOI":"10.1021\/acs.jmedchem.2c00758","article-title":"Optimization of the prodrug moiety of remdesivir to improve lung exposure\/selectivity and enhance anti-SARS-CoV-2 activity","volume":"65","author":"Hu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115763_bib43","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1021\/acsmedchemlett.7b00277","article-title":"Anchimerically activatable antiviral ProTides","volume":"8","author":"Okon","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115763_bib44","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1021\/acsinfecdis.0c00091","article-title":"In vitro and in vivo characterization of the anti-zika virus activity of ProTides of 2'-C-beta-Methylguanosine","volume":"6","author":"Matos de Souza","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2023.115763_bib45","doi-asserted-by":"crossref","first-page":"8131","DOI":"10.1021\/acs.jmedchem.7b00916","article-title":"Anchimerically activated ProTides as inhibitors of cap-dependent translation and inducers of chemosensitization in mantle cell lymphoma","volume":"60","author":"Okon","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115763_bib46","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1021\/jm9007856","article-title":"The application of phosphoramidate protide technology to acyclovir confers anti-HIV inhibition","volume":"52","author":"Derudas","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115763_bib47","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1016\/j.bmc.2011.05.037","article-title":"Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides","volume":"19","author":"Quintiliani","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115763_bib48","doi-asserted-by":"crossref","first-page":"16422","DOI":"10.1021\/acs.jmedchem.1c01908","article-title":"New heights for ProTides?","volume":"64","author":"Ballatore","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115763_bib49","doi-asserted-by":"crossref","first-page":"16703","DOI":"10.1021\/acs.jmedchem.1c01490","article-title":"Aryloxy pivaloyloxymethyl prodrugs as nucleoside monophosphate prodrugs","volume":"64","author":"Alanazi","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115763_bib50","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/10717544.2016.1250140","article-title":"Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique","volume":"24","author":"Khames","year":"2017","journal-title":"Drug Deliv."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423007304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423007304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:00:22Z","timestamp":1759330822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423007304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":50,"alternative-id":["S0223523423007304"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115763","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel ProTide prodrugs of 5-fluoro-2\u2032-deoxyuridine for the treatment of liver cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115763","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115763"}}